What is the price-to-earnings ratio of Zai Lab?
The price-earnings ratio of Zai Lab is currently 4.46.
Zai Lab P/S 2024
Zai Lab P/S
4.46
Ticker
9688.HK
ISIN
KYG9887T1085
WKN
A2DX7H
As of Jul 1, 2024, Zai Lab's P/S ratio stood at 4.46, a -62.65% change from the 11.94 P/S ratio recorded in the previous year.
The Zai Lab P/S history
Zai Lab Aktienanalyse
What does Zai Lab do?
Zai Lab Ltd is a biotech company based in Shanghai, China, that focuses on the development and commercialization of innovative drugs and therapies for unmet medical needs. The company's history dates back to 2014 when Dr. Samantha Du, an experienced pharma executive, founded the company to realize her vision of a modern, science-based biotech company in China. Zai Lab's business model is based on several strategic pillars. On one hand, the company collaborates with leading pharma and biotech research centers to discover, develop, and market new active ingredients and therapies. On the other hand, Zai Lab also promotes the acquisition of promising companies and technologies to strengthen its innovative power and expand its product portfolio. Another important aspect of Zai Lab's business model is its close collaboration with the Chinese government and healthcare system to simplify and improve access to new drugs and therapies for patients in China. Zai Lab operates in various business areas and markets to cover a wide range of medical needs. One of Zai Lab's main areas is oncology pharmaceuticals used to treat cancer. The company has focused primarily on novel active ingredients that have the potential to selectively target certain types of cancer cells while sparing healthy cells. Zai Lab's key oncology products include Niraparib, a PARP inhibitor for the treatment of ovarian cancer, and ZL-2301, a SHRPI inhibitor for the treatment of liver and lung cancer. Another important business area for Zai Lab is immunology and autoimmunity. Here, the company develops new therapies and medications that can modulate and regulate the immune system in certain disease conditions. One of the most promising products is the drug FOLFIRINOX, an immunomodulator for the treatment of chronic inflammatory bowel diseases. In addition to oncology and immunology, Zai Lab is also involved in other areas of medicine such as gastroenterology, infectious diseases, and neuroscience. In these fields, the company develops new antibiotics, vaccines, and medications for the treatment of diseases such as hepatitis B, Lyme disease, and Alzheimer's. Overall, Zai Lab aims to improve the health and well-being of patients in China and worldwide through its broad product range and innovation power. In recent years, Zai Lab has written an impressive growth story. The company has raised several million dollars in investments since its inception and has built a strong network and collaboration with other companies. Recently, Zai Lab has also attracted additional investors through IPOs in Hong Kong and New York, further strengthening its position as a leading biotech company in China. Overall, Zai Lab is an emerging biotech company that aims to fulfill medical needs in China and worldwide with its broad range of products and services and its innovation power. The company relies on close collaboration with leading research centers, companies, and government agencies, and strives to improve the health and well-being of patients worldwide. Zai Lab ist eines der beliebtesten Unternehmen auf Eulerpool.com.P/S Details
Decoding Zai Lab's P/S Ratio
Zai Lab's Price to Sales (P/S) Ratio is a crucial financial metric that measures the company's market valuation relative to its total sales revenue. It's calculated by dividing the company's market capitalization by its total sales over a specific period. A lower P/S ratio can indicate that the company is undervalued, while a higher ratio may suggest overvaluation.
Year-to-Year Comparison
Comparing Zai Lab's P/S ratio yearly provides insights into how the market perceives the company’s value relative to its sales. An increasing ratio over time can indicate growing investor confidence, while a decreasing trend might reflect concerns about the company’s revenue generation capabilities or market conditions.
Impact on Investments
The P/S ratio is instrumental for investors evaluating Zai Lab's stock. It offers insights into the company’s efficiency in generating sales and its market valuation. Investors use this ratio to compare similar companies within the same industry, aiding in selecting stocks that offer the best value for investment.
Interpreting P/S Ratio Fluctuations
Variations in Zai Lab’s P/S ratio can result from changes in the stock price, sales revenue, or both. Understanding these fluctuations is crucial for investors to evaluate the company’s current valuation and future growth potential, aligning their investment strategies accordingly.
Frequently Asked Questions about Zai Lab Stock
How has the price-earnings ratio of Zai Lab changed compared to last year?
The price-to-earnings ratio of Zai Lab has increased by -62.65% fallen (meaning "decreased" or "dropped") compared to last year.
What consequences does a high price-earnings ratio have for investors?
A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.
What does a low price-earnings ratio mean?
A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.
Is the price-earnings ratio of Zai Lab high compared to other companies?
Yes, the price-to-earnings ratio of Zai Lab is high compared to other companies.
How does an increase in the price-earnings ratio of Zai Lab affect the company?
An increase in the price-earnings ratio of Zai Lab would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.
How does a reduction in the price-to-earnings ratio of Zai Lab affect the company?
A decrease in the price-earnings ratio of Zai Lab would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.
What are some factors that influence the price-earnings ratio of Zai Lab?
Some factors that influence the price-earnings ratio of Zai Lab are the company's growth, financial position, industry development, and the overall economic situation.
How much dividend does Zai Lab pay?
Over the past 12 months, Zai Lab paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Zai Lab is expected to pay a dividend of 0 USD.
What is the dividend yield of Zai Lab?
The current dividend yield of Zai Lab is .
When does Zai Lab pay dividends?
Zai Lab pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Zai Lab?
Zai Lab paid dividends every year for the past 0 years.
What is the dividend of Zai Lab?
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
In which sector is Zai Lab located?
Zai Lab is assigned to the 'Health' sector.
Wann musste ich die Aktien von Zai Lab kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Zai Lab from 7/1/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 7/1/2024.
When did Zai Lab pay the last dividend?
The last dividend was paid out on 7/1/2024.
What was the dividend of Zai Lab in the year 2023?
In the year 2023, Zai Lab distributed 0 USD as dividends.
In which currency does Zai Lab pay out the dividend?
The dividends of Zai Lab are distributed in USD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Zai Lab
Our stock analysis for Zai Lab Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Zai Lab Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
